An open label trial of the effects and safety profile of extended-release tramadol in the management of chronic pain

Shao Keh Hsu, Chun Chang Yeh, Chii Jeng Lin, Yi Jer Hsieh

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objectives: Tramadol is a synthetic centrally-acting opioid analgesic. The newly developed extendedrelease formulation of tramadol offers a more stable plasma concentration and could improve patients' compliance. The purpose of this study was to evaluate the efficacy, safety, and adverse events of extended release tramadol in Taiwanese patients with moderate to severe chronic noncancer pain. Methods: Sixty-six patients with moderate to severe chronic noncancer pain previously treated with conventional tramadol but unsatisfied with its efficacy were enrolled from four medical centers. The patients received the extended-release tramadol once daily for a week. Results: The usage of extended-release tramadol was more efficacious as the patients' visual analog scale score dropped significantly (-16 ± 14.1). In this study, the reported adverse events were similar to those of previous studies. Thirty patients reported adverse events and one patient reported a serious adverse event but was justified unrelated to the study drug. The most common adverse event was dizziness, followed by vomiting, nausea, somnolence, and constipation in sequence. In this study, patients with dizziness were observed to have a lower initial pain score (p = 0.032). Furthermore, the rate of premature termination and dizziness was closely correlated (p = 0.027). Conclusion: Patients with chronic pain could obtain significantly better pain relief after the switch to larger doses of extended-release tramadol with safety and without severe adverse effects in a short period of time. Less severe adverse effects (no life-threatening event) was the leading cause of premature termination.

Original languageEnglish
Pages (from-to)101-105
Number of pages5
JournalActa Anaesthesiologica Taiwanica
Volume50
Issue number3
DOIs
Publication statusPublished - 2012 Sep

Fingerprint

Tramadol
Chronic Pain
Safety
Dizziness
Pain
Constipation
Patient Compliance
Visual Analog Scale
Nausea
Opioid Analgesics
Vomiting

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine

Cite this

@article{10a383df35b048bfa581ced8ed7f3b4b,
title = "An open label trial of the effects and safety profile of extended-release tramadol in the management of chronic pain",
abstract = "Objectives: Tramadol is a synthetic centrally-acting opioid analgesic. The newly developed extendedrelease formulation of tramadol offers a more stable plasma concentration and could improve patients' compliance. The purpose of this study was to evaluate the efficacy, safety, and adverse events of extended release tramadol in Taiwanese patients with moderate to severe chronic noncancer pain. Methods: Sixty-six patients with moderate to severe chronic noncancer pain previously treated with conventional tramadol but unsatisfied with its efficacy were enrolled from four medical centers. The patients received the extended-release tramadol once daily for a week. Results: The usage of extended-release tramadol was more efficacious as the patients' visual analog scale score dropped significantly (-16 ± 14.1). In this study, the reported adverse events were similar to those of previous studies. Thirty patients reported adverse events and one patient reported a serious adverse event but was justified unrelated to the study drug. The most common adverse event was dizziness, followed by vomiting, nausea, somnolence, and constipation in sequence. In this study, patients with dizziness were observed to have a lower initial pain score (p = 0.032). Furthermore, the rate of premature termination and dizziness was closely correlated (p = 0.027). Conclusion: Patients with chronic pain could obtain significantly better pain relief after the switch to larger doses of extended-release tramadol with safety and without severe adverse effects in a short period of time. Less severe adverse effects (no life-threatening event) was the leading cause of premature termination.",
author = "Hsu, {Shao Keh} and Yeh, {Chun Chang} and Lin, {Chii Jeng} and Hsieh, {Yi Jer}",
year = "2012",
month = "9",
doi = "10.1016/j.aat.2012.08.008",
language = "English",
volume = "50",
pages = "101--105",
journal = "Asian Journal of Anesthesiology",
issn = "2468-824X",
publisher = "Elsevier Taiwan LLC",
number = "3",

}

An open label trial of the effects and safety profile of extended-release tramadol in the management of chronic pain. / Hsu, Shao Keh; Yeh, Chun Chang; Lin, Chii Jeng; Hsieh, Yi Jer.

In: Acta Anaesthesiologica Taiwanica, Vol. 50, No. 3, 09.2012, p. 101-105.

Research output: Contribution to journalArticle

TY - JOUR

T1 - An open label trial of the effects and safety profile of extended-release tramadol in the management of chronic pain

AU - Hsu, Shao Keh

AU - Yeh, Chun Chang

AU - Lin, Chii Jeng

AU - Hsieh, Yi Jer

PY - 2012/9

Y1 - 2012/9

N2 - Objectives: Tramadol is a synthetic centrally-acting opioid analgesic. The newly developed extendedrelease formulation of tramadol offers a more stable plasma concentration and could improve patients' compliance. The purpose of this study was to evaluate the efficacy, safety, and adverse events of extended release tramadol in Taiwanese patients with moderate to severe chronic noncancer pain. Methods: Sixty-six patients with moderate to severe chronic noncancer pain previously treated with conventional tramadol but unsatisfied with its efficacy were enrolled from four medical centers. The patients received the extended-release tramadol once daily for a week. Results: The usage of extended-release tramadol was more efficacious as the patients' visual analog scale score dropped significantly (-16 ± 14.1). In this study, the reported adverse events were similar to those of previous studies. Thirty patients reported adverse events and one patient reported a serious adverse event but was justified unrelated to the study drug. The most common adverse event was dizziness, followed by vomiting, nausea, somnolence, and constipation in sequence. In this study, patients with dizziness were observed to have a lower initial pain score (p = 0.032). Furthermore, the rate of premature termination and dizziness was closely correlated (p = 0.027). Conclusion: Patients with chronic pain could obtain significantly better pain relief after the switch to larger doses of extended-release tramadol with safety and without severe adverse effects in a short period of time. Less severe adverse effects (no life-threatening event) was the leading cause of premature termination.

AB - Objectives: Tramadol is a synthetic centrally-acting opioid analgesic. The newly developed extendedrelease formulation of tramadol offers a more stable plasma concentration and could improve patients' compliance. The purpose of this study was to evaluate the efficacy, safety, and adverse events of extended release tramadol in Taiwanese patients with moderate to severe chronic noncancer pain. Methods: Sixty-six patients with moderate to severe chronic noncancer pain previously treated with conventional tramadol but unsatisfied with its efficacy were enrolled from four medical centers. The patients received the extended-release tramadol once daily for a week. Results: The usage of extended-release tramadol was more efficacious as the patients' visual analog scale score dropped significantly (-16 ± 14.1). In this study, the reported adverse events were similar to those of previous studies. Thirty patients reported adverse events and one patient reported a serious adverse event but was justified unrelated to the study drug. The most common adverse event was dizziness, followed by vomiting, nausea, somnolence, and constipation in sequence. In this study, patients with dizziness were observed to have a lower initial pain score (p = 0.032). Furthermore, the rate of premature termination and dizziness was closely correlated (p = 0.027). Conclusion: Patients with chronic pain could obtain significantly better pain relief after the switch to larger doses of extended-release tramadol with safety and without severe adverse effects in a short period of time. Less severe adverse effects (no life-threatening event) was the leading cause of premature termination.

UR - http://www.scopus.com/inward/record.url?scp=84871436100&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871436100&partnerID=8YFLogxK

U2 - 10.1016/j.aat.2012.08.008

DO - 10.1016/j.aat.2012.08.008

M3 - Article

C2 - 23026168

AN - SCOPUS:84871436100

VL - 50

SP - 101

EP - 105

JO - Asian Journal of Anesthesiology

JF - Asian Journal of Anesthesiology

SN - 2468-824X

IS - 3

ER -